Accretion Pharmaceuticals IPO Set To Open For Subscription On May 14

Accretion Pharmaceuticals Limited, incorporated in 2012, operates in the pharmaceutical sector, specialising in the manufacturing of a broad range of healthcare products. Its portfolio includes tablets, capsules, oral liquids, medicated shampoos, external preparations such as ointments and creams, and oral powders. The company also offers contract manufacturing services and has established itself as a growing player in the healthcare manufacturing space.

IPO Details and Subscription Information

Accretion Pharmaceuticals is launching an Initial Public Offering (IPO) through a book-building process, amounting to ₹29.75 crore. This issue is comprised entirely of a fresh issue totalling 29.46 lakh equity shares. The IPO opens for subscription on 14 May 2025 and closes on 16 May 2025. The allotment is expected to be finalised on 19 May 2025, and the shares are proposed to be listed on the NSE SME platform on 21 May 2025.

The IPO price band has been fixed between ₹96 and ₹101 per share. Retail investors can apply for a minimum of one lot, equivalent to 1,200 shares, requiring an investment of ₹1,15,200. However, to strengthen chances of allotment, applying at the cutoff price is suggested, raising the investment to ₹1,21,200. High Net-Worth Individuals (HNIs) must apply for a minimum of two lots (2,400 shares), amounting to ₹2,42,400.

Jawa Capital Services Private Limited is acting as the Book Running Lead Manager, and Kfin Technologies Limited is the registrar. Gretex Share Broking Private Limited is the market maker for the IPO.

Company Background and Business Model

Founded in 2012, Accretion Pharmaceuticals has built a robust manufacturing base covering solid, liquid, and semi-solid dosage forms. The company supplies the domestic market and undertakes contract manufacturing for third parties.

Its product lines include oral tablets and capsules, syrups, creams, gels, medicated shampoos, powders, and mouthwashes. With an emphasis on quality and affordability, the company aims to strengthen its market presence and operational scale, supported by strategic capital deployment through the IPO.

Objectives of the Issue

Read More: Mouri Tech Limited Re-Files DRHP with SEBI for ₹1,500 Crore IPO

May 08, 2025

Conclusion

The IPO marks a pivotal moment in Accretion Pharmaceuticals’ journey. With clear plans for expansion, debt management, and improved liquidity, the company is positioning itself for sustainable growth. Investors participating in this SME IPO will be supporting a firm with both operational strength and growth potential.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.